Acknowledgements This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency
Stack: Retatrutide: Research-dose titration (start low, escalate gradually per Phase 2 trial protocol) Ipamorelin/CJC-1295: 100-200mcg pre-sleep daily Why this combination works: Retatrutide targets the GLP-1, GIP, and glucagon receptors to suppress appetite, improve insulin sensitivity, and drive fat oxidation
Springer International Publishing, Cham Singh S, Bakshi M (2000) Guidance on conduct of stress tests to determine inherent stability of drugs
The liver benefits require attention, particularly for patients with fatty liver disease
Tirzepatide (Zepbound, Monjaro) A dual-hormone (GLP-1/GIP) medication designed to reduce hunger and support meaningful weight loss under medical guidance